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Abstract
Background: With the advent of new and more efficient anti-androgen drugs targeting androgen receptor (AR) in
breast cancer (BC) is becoming an increasingly important area of investigation. This would potentially be most useful in
triple negative BC (TNBC), where better therapies are still needed. The assessment of AR status is generally performed
on the primary tumor even if the tumor has already metastasized. Very little is known regarding discrepancies of AR
status during tumor progression. To determine the prevalence of AR positivity, with emphasis on TNBCs, and to
investigate AR status during tumor progression, we evaluated a large series of primary BCs and matching metastases
and recurrences.
Methods: AR status was performed on 356 primary BCs, 135 matching metastases, and 12 recurrences using a next-
generation Tissue Microarray (ngTMA). A commercially available AR antibody was used to determine AR-status by
immunohistochemistry. AR positivity was defined as any nuclear staining in tumor cells ≥1 %. AR expression was
correlated with pathological tumor features of the primary tumor. Additionally, the concordance rate of AR expression
between the different tumor sites was determined.
Results: AR status was positive in: 87 % (307/353) of primary tumors, 86.1 % (105/122) of metastases, and in 66.7
% (8/12) of recurrences. TNBC tested positive in 11.4 %, (4/35) of BCs. A discrepant result was seen in 4.3 % (5/117) of
primary BC and matching lymph node (LN) metastases. Three AR negative primary BCs were positive in the matching
LN metastasis, representing 17.6 % of all negative BCs with lymph node metastases (3/17). Two AR positive primary BCs
were negative in the matching LN metastasis, representing 2.0 % of all AR positive BCs with LN metastases (2/100). No
discrepancies were seen between primary BC and distant metastases or recurrence (n = 17).
Conclusions: Most primary (87 %) and metastasized (86.1 %) BCs are AR positive including a significant fraction of
TNBCs (11.4 %). Further, AR status is highly conserved during tumor progression and a change only occurs in a
small fraction (4.1 %). Our study supports the notion that targeting AR could be effective for many BC patients
and that re-testing of AR status in formerly negative or mixed type BC’s is recommended.
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Background
The androgen receptor (AR) is located on the long arm
of the X chromosome (Xq12) and acts, upon ligand
binding, as a transcription factor [1]. AR signaling has
well documented roles in embryogenesis of both genders
and plays an important role in mammary gland develop-
ment in females [2]. The role of AR signaling in breast
carcinogenesis is seemingly complex and is currently an
area of intense investigation. AR signaling may have a
dual role of both inhibiting and promoting cell prolifera-
tion. Inhibition of proliferation and cell growth was seen
in hormone receptor positive and triple negative BC
(TNBC) cell lines [3–5], respectively. Tumor growth due
to AR activity was also shown for apocrine BCs [6]. In a
Phase II clinical trial it was shown that patients with AR
positive BC had a benefit from anti-androgenic therapy
[7] indicating that targeting AR might be a therapeutic
option. These results led to many subsequent clinical tri-
als investigating anti-androgen therapy in BCs patients,
especially in patients where no other targeted therapies
were available, as in triple negative BC, and in patients
with advanced disease [8] (ClinicalTrials.gov). Therefore,
it is of great clinical value to know the prevalence of AR
positivity in BC at all stages and molecular subtypes.
Since receptor conversion between primary and meta-
static sites has been observed for estrogen (ER), proges-
terone (PgR) and Her2 receptor [9, 10], we also assessed
how AR expression may change with metastasis and re-
currence. AR changes during tumor progression would
have important clinical implications for patient selection
of anti-AR therapy.
Methods
Patients
The patient cohort described in this study has been
previously reported [11]. Briefly, patients diagnosed
with therapy naïve, unilateral minimum pT1b primary
BC diagnosed between 2005 and 2011 at the Institute
of Pathology, University of Bern, Switzerland were in-
cluded. Next generation tissue microarrays (ngTMAs)
were constructed from the primary BCs, matched dis-
tant or lymph node metastases, and local and distant
recurrences. Recurrence was defined as tumor mani-
festation >3 months (median: 24 months; range: 8–82
months) after initial surgery of the primary tumor.
From 135 patients matching metastases, of these in-
cluded, 129 axillary lymph nodes and 6 distant metasta-
ses were available. From 12 patients recurrences were
available included 10 local-regional recurrences and 2
distant recurrences. The median age at diagnosis was
67 years (range: 31–98). The study was approved by the
ethical committee of the University of Bern (Registration:
200/2014). The approval of the ethical committee includes
a waiver of consent for retrospective TMA based studies
based on material archived at the Institute of Pathology,
University of Bern, Switzerland. Patient characteristics are
recorded in Table 1.
Next-generation Tissue Microarray (ngTMA)
Prior to ngTMA construction all primary BCs, positive
lymph nodes, distant metastasis, and recurrences under-
went pathological review (CT, MT, KP) for diagnostic
confirmation. The primary tumors were classified accord-
ing to the WHO classification 2013 [12]. ngTMA con-
struction was performed as previously described [11, 13].
In brief, for TMA construction the most suitable, as per
the discretion of the pathologists, formalin-fixed paraffin-
embedded (FFPE) tissue block, was selected for each
tumor sample. Corresponding H&E slides were scanned
and up-loaded on the digital platform. The annotations
were made on the scanned slides and afterwards the auto-
mated arrayer precisely punched the annotated areas out
of the donor block into a new recipient block (ngTMA).
Multiple punches from primary tumors, lymph nodes
and recurrences were taken for ngTMA construction.
In 97.8 % the primary tumors were represented by 6
punches. From the metastasis and recurrence, 2 punches
(duplicates) were included in 82.2 % of the cases.
Immunohistochemistry of androgen receptor
For the assessment of AR status a monoclonal anti-
human androgen receptor antibody (clone AR441, Dako,
Glostrup, Denmark) was used (1:100 dilution). A positive
AR status was defined as average of ≥1 % positive tumor
nuclei regardless of staining intensity as previously de-
scribed [14]. The AR status of each tumor and corre-
sponding metastasis or recurrence samples was evaluated
without knowledge of sample annotation. The scoring was
conducted according to the REMARK Guidelines for bio-
markers [15].
Results on ER, PgR, Her2, and MIB-1 were available
from our previous study [11], and the tumors were clas-
sified into the molecular subtypes according to the St.
Gallen 2013 criteria [16].
Statistics
The Chi-Square test was used to calculate significant dif-
ferences between categorical variables. A p-value <0.05
was considered statistically significant. Analyses were car-
ried out using SPSS 21 (IBM, Armonk, USA).
Results
AR status was informative in 99.2 % (353/356) of pri-
mary BCs, 90.4 % (122/135) of metastases (lymph nodes:
117/129; distant metastasis: 5/6) and in 100 % (12/12) of
the recurrences (loco-regional: 10/12; distant: 2/12). The
majority of BCs were AR positive (≥75 %) with the ex-
ception of BCs with medullary-like features (36.4 %).
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AR status in primary BC and correlation with pathological
parameters
Primary BCs were AR positive in 87 % (307/353) and
showed a significant (p < 0.001) correlation with a positive
ER (96.7 %; 295/305) and PgR (96.9 %; 247/255) status,
and a low proliferation index of <20 % (93.2 %; 275/295).
ER negative primary BCs showed a positive AR status
in 25 % (12/48), PgR negative BCs in 61.2 % (60/98),
while ER and PgR negative BCs had a positive AR sta-
tus in 26.7 % (12/45). A negative AR status correlated
significantly (p < 0.001) with high tumor grade (G3)
(37/120).
Luminal A were AR positive in 98.5 % (192/195), lu-
minal B (Her2 negative) in 91.4 % (74/81), and all lu-
minal B (Her2 positive) were AR positive (24/24). The
Her2 and TNBC subtype were AR positive in 80 % (8/
10) and in 11.4 % (4/35), respectively.
AR status in metastases and recurrence
Lymph node metastases were AR positive in 85.5 %
(100/117), distant metastases in 100 % (5/5) and recur-
rences in 66.7 % (8/12). The mean percentage of AR
positive cells among recurrent BCs was: 43.1 % in pri-
mary tumors and 39.9 % in recurrences. AR negative
BCs stayed negative in primary tumors and recurrences
(mean: 0 % AR staining each). The results are summa-
rized in Table 2.
Discordant AR status
A discordant AR status between primary BC and
matched metastatic samples was observed in 4.1 % (5/
122) of cases tested. However, a discrepant AR status
was only seen between primary BC and matched lymph
node metastases (4.3 %; 5/117), but not between primary
BC and distant metastasis. Two AR positive primary
BCs had a negative corresponding lymph node metasta-
sis (2.0 %; 2 of 100 AR positive primary BC with evalu-
able matching lymph nodes). Three negative primary
BCs had an AR positive lymph node metastasis (17.6 %;
3 of 17 AR negative primary BCs with evaluable match-
ing lymph nodes). No discordant AR status was ob-
served between the primary BC and distant metastases
or recurrences.
Table 1 Patients characteristics (n = 356)
Features n (%)
Age at diagnosis median 67 yrs (range:31–98)
Histological subtypes
No special type (NST) 253 (71.1)
Lobular 51 (14.3)
Mucinous 13 (3.7)
Carcinoma with medullary-like features 11 (3.1)
Ductulo-lobular 6 (1.7)
Tubular 4 (1.1)
Micropapillary 3 (0.8)
Cribriform 2 (0.6)
Glycogen rich 1 (0.3)
Mixed 12 (3.3)
Grading (Nottingham)
G1 41 (11.5)
G2 194 (54.5)
G3 121 (34.0)
T-category (UICC 7th edition)
T1 150 (42.1)
T2 167 (46.9)
T3 21 (5.9)
T4 18 (5.1)
N-category (UICC 7th edition)
N0 146 (41.0)
N1mi 18 (5.1)
N1 102 (28.6)
N2 27 (7.6)
N3 22 (6.2)
no lymph nodes 41 (11.5)
Estrogen receptor
positive (≥1 %) 308 (86.5)
negative (<1 %) 48 (13.5)
Progesterone receptor
positive (≥1 %) 258 (72.5)
negative (<1 %) 98 (27.5)
Her2 Status
positive 37 (10.4)
negative 316 (88.7)
Equivocal 1 (0.3)
no data 2 (0.6)
Proliferation fraction (MIB-1)
High (≥20 %) 57 (16.0)
low (<20 %) 297 (83.4)
no data 2 (0.6)
Table 1 Patients characteristics (n = 356) (Continued)
Molecular subtypes (St. Gallen 2013)
Luminal A 197 (55.4)
Luminal B (Her2 negative) 82 (23.1)
Luminal B (Her2 positive) 24 (6.7)
Her2 10 (2.8)
Triple negative 35 (9.8)
no data 8 (2.2)
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Re-evaluation of discordant AR status
To confirm the discordant results, we re-evaluated the 5
discordant primary BC and their matching lymph node
metastases. In two discordant cases (ID 237, 248), the
primary BC was negative and their matched metastases
were positive, but the AR status was close to the cut-off
of ≥1 % for each. In another case (ID 204), the primary
was negative but the lymph node metastasis was posi-
tive. In this case, the final score was not close to the cut-
off of ≥1 %. In the fourth BC (ID 47), the primary BC
was positive but the lymph node tissue was negative.
The lymph node metastasis in this case was frozen prior
to formalin-fixation (sentinel) and showed some crush
artifacts, which could explain the negative score. The
fifth case (ID 356) was of the ductulo-lobular histological
subtype. The primary BC showed punches with both, a
negative and a positive AR status. The primary tumor
was signed off as AR positive but the metastasis was
negative. The results are summarized in Table 3 and ex-
amples of discordance are given in Fig. 1.
Discussion
For decades, the steroid hormone receptors ER and PgR
have been well known therapeutic targets in BC [17] but
considering AR therapy lagged in BC. In part, this lag-
ging could be attributed to failure of early attempts of
targeting AR to show benefit in BC [18]. Nevertheless,
targeting AR is now becoming increasingly researched
especially in patients with few targeted therapeutic op-
tions such as patients with TNBCs. Certainly, based on
the results of our study and others [5] one could argue
that anti-androgenic therapy should also be considered
in AR positive BCs with ER and PgR positive, advanced,
and recurrent disease, and/or in tumors which have be-
come resistant to previous anti-estrogen therapy.
From a biological and therapeutic point of view, the
dynamics of AR status during tumor progression is an
important consideration. In a recent study, which in-
cluded a small series of TNBC with matched recurrences
(n = 16) and lymph node metastases (n = 46), it was
shown that AR discrepancies between primary tumors
and metastasis did not occur [19]. Our study confirmed,
that AR status is highly preserved during tumor progression,
Table 2 Primary breast cancer and androgen receptor status
Features AR status n (%)
Positive
(≥1 %)
Negative
(<1 %)
p-value
Primary BC 307 (87.0) 46 (13.0)
Metastases 105 (86.1) 17 (13.9)
Recurrences 8 (66.7) 4 (33.3)
Histological subtypes
No special type (NST) 218 (86.5) 34 (13.5)
Lobular 49 (98.0) 1 (2.0)
Mucinous 10 (83.3) 2 (16.7)
Carcinoma with medullary-like
features
4 (36.4) 7 (63.6)
Ductulo-lobular 6 (100) 0 (0)
Tubular 3 (75) 1 (25)
Micropapillary 3 (100) 0 (0)
Cribriform 2 (100) 0 (0)
Glycogen rich 1 (100) 0 (0)
Mixed 12 (100) 0 (0)
Grading (Nottingham)
G1 38 (92.7) 3 (7.3)
G2 186 (96.9) 6 (3.1)
G3 83 (69.2) 37 (30.8) <0.001
T-category (UICC 7th edition)
1 138 (93.2) 10 (6.8)
2 137 (82.5) 29 (17.5) 0.017
3 16 (76.2) 5 (23.8)
4 16 (88.9) 2 (11.1)
N-category (UICC 7th edition)
N0 123 (85.4) 21 (14.6) 0.595
N1mi 18 (100.0) 0 (0.0)
N1 87 (86.1) 14 (13.9)
N2 21 (77.8) 6 (22.2)
N3 21 (95.5) 1 (0.5)
Estrogen receptor
Positive (≥1 %) 295 (96.7) 10 (3.3) <0.0001
Negative (<1 %) 12 (25) 36 (75)
Progesterone receptor
Positive (≥1 %) 247 (96.9) 8 (3.1) <0.0001
Negative (<1 %) 60 (61.2) 38 (38.8)
Her2 Status
Positive 34 (91.9) 3 (8.1) 0.585
Negative 270 (86.3) 43 (13.7)
Equivocal 1 (100) 0 (0)
Proliferation fraction (MIB-1)
High (≥20 %) 31 (55.4) 25 (44.6) <0.0001
Low (<20 %) 275 (93.2) 20 (6.8)
Table 2 Primary breast cancer and androgen receptor status
(Continued)
Molecular subtypes (St. Gallen 2013)
Luminal A 192 (98.5) 3 (1.5) <0.0001
Luminal B (Her2 negative) 74 (91.4) 7 (8.6)
Luminal B (Her2 positive) 24 (100.0) 0 (0.0)
Her2 8 (80) 2 (20)
Triple negative 4 (11.4) 31 (88.6)
AR Androgen receptor, BC Breast cancer
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Table 3 Discrepant AR status of primary BC and matched lymph node metastasis
Androgen receptor status
Patient ID Primary BC Lymph node metastasis Comments
204 negative positive Fixation? tumor heterogeneity?
237 negative positive Evaluation (staining close to the cut-off of ≥1 %)?
348 negative positive Evaluation (staining close to the cut-off of ≥1 %)?
47 positive negative Pre-analytic handling? fixation? tumor heterogeneity?
356 positive negative Tumor heterogeneity
BC Breast cancer
Fig. 1 Examples of discrepant cases. a-f: TMA punches of matched primary BCs and matched lymph node metastases stained for the androgen
receptor (AR) (100x magnification). a-b: patient ID 348; c-d: patient ID 47, e-f: patient ID 356. a Primary no special type (NST) BC with a negative
androgen receptor (AR) status (<1 % positive tumor cells) and matched lymph node metastasis (b) with a positive, nuclear brown AR staining (1 %
positive tumor cells). c Positive primary NST BC (5 % positive tumor cells) with some cytoplasmatic background and matched lymph node metastasis
(d) with a negative AR status. The black arrow is pointing to the metastatic cells. On the bottom of the arrow some crush artifacts are visible.
e Ductulo-lobular, primary BC with a positive and a negative (inlet) tumor component for AR. The matched lymph node metastasis (f) shows
a negative AR status and some cytoplasmatic background
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but we did identify a few samples (n = 5) with discordant
AR status from the primary tumor to the lymph node
metastases. Due to the small number of distant metastases
(n = 5) and recurrences (n = 12) included in our study and
in the study by McNamara et al. [19], the degree to which
AR discrepancies occurs in these cases may not have been
adequately captured.
In general, while receptor conversion can occur be-
cause of true molecular evolutionary changes associ-
ated with tumor progression, it can also be due to
the inherent subjective nature of immunohistochemi-
cal evaluation. This can especially be witnessed when
pathologist-assigned scores are close to the cut-off
values of calling a tumor positive or negative for any
given marker and was the reason for the perceived
discrepant AR status in 2/5 cases in this study. This
is a well-known and unresolved problem in the evalu-
ation of biomarkers by pathologists where intra- and
inter-observer variability can lead to discrepant re-
sults. This has been especially true for the assessment
of the proliferation fraction (MIB-1) in BC [20, 21].
Other issues leading to potential discordant scores be-
tween matched samples is pre-analytical handling of the
specimens and whether the specimens were optimally
fixed, which can impair staining [22]. Tumor heterogen-
eity also plays an important role in interpreting results
obtained from few selected regions in a tumor. Previous
studies have demonstrated that 4 to 5 tumor punches on
an array was sufficient to validate the use of a biomarker
on a TMA [23]. Therefore, our ngTMA harbored mul-
tiple tissue punches to represent the tumor. However,
the use of ngTMA to validate protein expression bears
advantages and disadvantage.
Lastly, since we observed that 3/17 (17.6 %) AR nega-
tive primary BCs showed an AR positive lymph node
metastases, we recommend re-testing of previous AR
negative tumors. Additionally, re-testing of BCs with
morphologically mixed components would be desirable.
It has to be discussed with the oncologists if AR positive
primary tumors need to be re-assessed on metastases or
recurrences.
Conclusions
In summary, AR positivity is very frequently found in
BC regardless of the disease site and immunophenotype.
Therefore, AR targeted therapy might be a warranted
treatment option for many BC patients. Furthermore, it
appears that AR status is highly preserved during tumor
progression but discordance between primary and meta-
static sites may occur in a small fraction of tumors.
Hence, we recommend re-testing of AR status in previ-
ously AR negative primary tumors and BCs with mor-
phologically mixed components.
Competing interests
The authors declare that they have no conflict of interest.
Authors’ contributions
AG drafted the manuscript, helped in ngTMA construction, helped in the
assessment of tumor grading, scoring of ER, PgR, AR, Her2 and MIB-1, collected
substantially patient data and approved the final manuscript. MT and KP
reviewed breast cancer samples, helped in sample annotations, and approved
the final manuscript. CL helped in ngTMA construction and sample annotations
and approved the final manuscript. RD helped drafting the manuscript,
provided intellectual input and approved the final manuscript. NC collected
clinical data, provided intellectual input and approved the final
manuscript. BS gave intellectual input, helped writing the manuscript and
approved the final manuscript. MZ provided intellectual input for the study
design and approved the final manuscript. CT designed the study, reviewed
breast cancer samples, scored ER, PgR, Her2, AR and MIB-1 and finalized the
manuscript.
Acknowledgement and funding information
The authors thank the tissue bank Bern and the Translational Research Unit
(TRU) for the ngTMA construction. We thank Curadis, Inc. (Germany) for
supporting this study.
This is a study from the Biobank Bern, University of Bern and the Breast
Cancer Center, Inselspital Bern, Switzerland.
We thank Wolfgang Schoenfeld for the critical review of the manuscript.
Author details
1Division of Clinical Pathology, Institute of Pathology, University of Bern, Bern,
Switzerland. 2Department of Surgery, University Hospital Basel, Basel,
Switzerland. 3Department of Radiation Oncology, Bern University Hospital,
and University of Bern, Freiburgstrasse, 3010 Bern, Switzerland. 4Translational
Genomics Research Institute, Phoenix, USA. 5Department of Medical
Oncology, Bern University Hospital, Bern, Switzerland. 6University Cancer
Center, Breast Center, Inselspital Bern, Bern, Switzerland. 7Department of
Translational Molecular Pathology, University of Texas MD Anderson Cancer
Center Life Science Plaza, 2130 W. Holcombe, Blvd. Unit 2951, Houston, TX
77030, USA.
Received: 1 June 2015 Accepted: 3 November 2015
References
1. Matsumoto T, Shiina H, Kawano H, Sato T, Kato S. Androgen receptor
functions in male and female physiology. J Steroid Biochem Mol Biol.
2008;109:236–41.
2. Chang C, Lee SO, Wang RS, Yeh S, Chang TM. Androgen receptor (AR)
physiological roles in male and female reproductive systems: lessons learned
from AR-knockout mice lacking AR in selective cells. Biol Reprod. 2013;89:21.
3. Lanzino M, Sisci D, Morelli C, Garofalo C, Catalano S, Casaburi I, et al.
Inhibition of cyclin D1 expression by androgen receptor in breast cancer
cells–identification of a novel androgen response element. Nucleic Acids
Res. 2010;38:5351–65.
4. Ando S, De AF, Rago V, Carpino A, Maggiolini M, Panno ML, et al. Breast cancer:
from estrogen to androgen receptor. Mol Cell Endocrinol. 2002;193:121–8.
5. Narayanan R, Ahn S, Cheney MD, Yepuru M, Miller DD, Steiner MS, et al.
Selective androgen receptor modulators (SARMs) negatively regulate
triple-negative breast cancer growth and epithelial:mesenchymal stem cell
signaling. PLoS One. 2014;9, e103202.
6. Fioretti FM, Sita-Lumsden A, Bevan CL, Brooke GN. Revising the role of the
androgen receptor in breast cancer. J Mol Endocrinol. 2014;52:R257–65.
7. Gucalp A, Tolaney S, Isakoff SJ, Ingle JN, Liu MC, Carey LA, et al. Phase II trial of
bicalutamide in patients with androgen receptor-positive, estrogen receptor-
negative metastatic Breast Cancer. Clin Cancer Res. 2013;19:5505–12.
8. Lehmann BD, Bauer JA, Schafer JM, Pendleton CS, Tang L, Johnson KC, et al.
PIK3CA mutations in androgen receptor-positive triple negative breast
cancer confer sensitivity to the combination of PI3K and androgen receptor
inhibitors. Breast Cancer Res. 2014;16:406.
9. Broom RJ, Tang PA, Simmons C, Bordeleau L, Mulligan AM, O’Malley FP,
et al. Changes in estrogen receptor, progesterone receptor and Her-2/neu
status with time: discordance rates between primary and metastatic breast
cancer. Anticancer Res. 2009;29:1557–62.
Grogg et al. BMC Cancer  (2015) 15:872 Page 6 of 7
10. Pusztai L, Viale G, Kelly CM, Hudis CA. Estrogen and HER-2 receptor
discordance between primary breast cancer and metastasis. Oncologist.
2010;15:1164–8.
11. Salhia B, Trippel M, Pfaltz K, Cihoric N, Grogg A, Ladrach C, et al. High tumor
budding stratifies breast cancer with metastatic properties. Breast Cancer
Res Treat. 2015;150:363–71.
12. Lakhani SR: Keynote Lecture: KN02 UPDATE ON WHO BREAST CLASSIFICAT.
Pathology 2014, 46 Suppl 2: S1.
13. Zlobec I, Suter G, Perren A, Lugli A. A next-generation tissue microarray
(ngTMA) protocol for biomarker studies. J Vis Exp. 2014;51893.
14. Safarpour D, Pakneshan S, Tavassoli FA. Androgen receptor (AR) expression
in 400 breast carcinomas: is routine AR assessment justified? Am J Cancer
Res. 2014;4:353–68.
15. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM.
Reporting recommendations for tumor marker prognostic studies (REMARK).
J Natl Cancer Inst. 2005;97:1180–4.
16. Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M,
Thurlimann B, et al. Personalizing the treatment of women with early breast
cancer: highlights of the St Gallen International Expert Consensus on the
Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013;24:2206–23.
17. Jordan VC. Tamoxifen: a most unlikely pioneering medicine. Nat Rev Drug
Discov. 2003;2:205–13.
18. Perrault DJ, Logan DM, Stewart DJ, Bramwell VH, Paterson AH, Eisenhauer
EA. Phase II study of flutamide in patients with metastatic breast cancer. A
National Cancer Institute of Canada Clinical Trials Group study. Invest New
Drugs. 1988;6:207–10.
19. McNamara KM, Yoda T, Miki Y, Nakamura Y, Suzuki T, Nemoto N, et al.
Androgen receptor and enzymes in lymph node metastasis and cancer
reoccurrence in triple-negative breast cancer. Int J Biol Markers.
2015;30(2):e184–9.
20. Varga Z, Diebold J, Dommann-Scherrer C, Frick H, Kaup D, Noske A, et al.
How reliable is Ki-67 immunohistochemistry in grade 2 breast carcinomas?
A QA study of the Swiss Working Group of Breast- and Gynecopathologists.
PLoS One. 2012;7:e37379.
21. Cserni G, Voros A, Liepniece-Karele I, Bianchi S, Vezzosi V, Grabau D, et al.
Distribution pattern of the Ki67 labelling index in breast cancer and its
implications for choosing cut-off values. Breast. 2014;23:259–63.
22. Neumeister VM, Anagnostou V, Siddiqui S, England AM, Zarrella ER,
Vassilakopoulou M, et al. Quantitative assessment of effect of preanalytic
cold ischemic time on protein expression in breast cancer tissues. J Natl
Cancer Inst. 2012;104:1815–24.
23. Goethals L, Perneel C, Debucquoy A, De SH, Borghys D, Ectors N, et al. A new
approach to the validation of tissue microarrays. J Pathol. 2006;208:607–14.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Grogg et al. BMC Cancer  (2015) 15:872 Page 7 of 7
